Education
About Us
Working with TipRanks
Follow Us
Viridian Therapeutics (VRDN)
NASDAQ:VRDN
VRDN Analyst Ratings
Strong Buy
14 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
VRDN Stock 12 Month Forecast
Average Price Target
$39.58
▲(43.93% Upside)
| Highest Price Target$61.00 | Average Price Target$39.58 | Lowest Price Target$13.95 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Goldman Sachs
$30→$40
Buy
45.45%
Upside
Reiterated
11/06/25
RBC Capital
$41→$45
Buy
63.64%
Upside
Reiterated
11/06/25
Oppenheimer
$36
Buy
30.91%
Upside
Reiterated
11/06/25
H.C. Wainwright
$34
Buy
23.64%
Upside
Reiterated
11/05/25
Wedbush
$42
Buy
52.73%
Upside
Reiterated
11/05/25
Needham
$34
Buy
23.64%
Upside
Reiterated
11/05/25
Viridian Therapeutics: Promising Future with Strategic Trials and Financial Stability6:44 PM 2025 ESTIMATE CHANGE Biotechnology Viridian Therapeutics, Inc. (VRDN) RATING BUY PRICE TARGET $34.00 PREV CLOSE $22.55 52-WEEK RANGE $9.90 - $27.20 3Q25 Recap; Veli BLA Submitted, Ph 3 REVEAL 2Q26 VRDN reported 3Q25 financials and provided a corporate update. While 3Q25 was eventful for VRDN, the 3Q25 update is a non-event due to recent newsflow. VRDN recently completed enrollment in the ph 3 REVEAL trials evaluating VRDN-003 (SC version of veli) and refined timelines for readouts to 1Q26 for REVEAL-2, ahead of a BLA filing by YE2026. The company also recently completed the BLA filing for veli. FDA acceptance in late- Dec/early-Jan will determine whether a Priority Review is granted for a potential mid-2026 approval.
BTIG
$61
Buy
121.82%
Upside
Reiterated
11/04/25
Viridian Therapeutics: Promising Future with Strategic Advancements and Financial BackingWe continue to see the data as considerably de-risked by THRIVE-1/2 given veligrotug and VRDN-003 share the same binding domain. We also expect payers to prefer an SC administered option, and we are not aware of any other publicly announced late-stage development efforts of an SC autoinjector IGF-1R Tx option besides VRDN-003. If this competitive positioning remains unchanged, we expect Viridian to corner most of the TED market later this decade with the best-in-category SC Tx option. If positive, REVEAL-1/2 are expected to support a VRDN-003 BLA submission in YE26.
LifeSci Capital
$46
Buy
67.27%
Upside
Reiterated
11/03/25
Viridian Therapeutics: Promising Prospects with Innovative TED Treatments and Financial Stability Justify Buy RatingDespite the ongoing government shutdown, Viridian (Nasdaq: VRDN) announced that it successfully submied a BLA in late October for veligrotug (an-IGF-1R mAb) in following “producve engagements with the FDA.” The filing was based on posive results from the THRIVE program in both acve and chronic TED paents (our notes HERE and HERE) and includes a request for Priority Review (supported by veligrotug’s Breakthrough Therapy Designaon), which could enable a mid-2026 commercial launch if approved. The FDA will decide whether to accept/file the BLA for review within 60 days of submission.
TD Cowen
―
Buy
―
Reiterated
11/03/25
Leerink Partners
―
Buy
―
Reiterated
10/21/25
Bloom Burton
$13.95
Buy
-49.28%
Downside
Reiterated
10/21/25
Stifel Nicolaus
$41
Buy
49.09%
Upside
Assigned
10/20/25
Jefferies
$44
Buy
60.00%
Upside
Reiterated
10/17/25
Evercore ISI
$38
Buy
38.18%
Upside
Reiterated
08/11/25
Wells Fargo
$26
Hold
-5.45%
Downside
Reiterated
08/06/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Goldman Sachs
$30→$40
Buy
45.45%
Upside
Reiterated
11/06/25
RBC Capital
$41→$45
Buy
63.64%
Upside
Reiterated
11/06/25
Oppenheimer
$36
Buy
30.91%
Upside
Reiterated
11/06/25
H.C. Wainwright
$34
Buy
23.64%
Upside
Reiterated
11/05/25
Wedbush
$42
Buy
52.73%
Upside
Reiterated
11/05/25
Needham
$34
Buy
23.64%
Upside
Reiterated
11/05/25
Viridian Therapeutics: Promising Future with Strategic Trials and Financial Stability6:44 PM 2025 ESTIMATE CHANGE Biotechnology Viridian Therapeutics, Inc. (VRDN) RATING BUY PRICE TARGET $34.00 PREV CLOSE $22.55 52-WEEK RANGE $9.90 - $27.20 3Q25 Recap; Veli BLA Submitted, Ph 3 REVEAL 2Q26 VRDN reported 3Q25 financials and provided a corporate update. While 3Q25 was eventful for VRDN, the 3Q25 update is a non-event due to recent newsflow. VRDN recently completed enrollment in the ph 3 REVEAL trials evaluating VRDN-003 (SC version of veli) and refined timelines for readouts to 1Q26 for REVEAL-2, ahead of a BLA filing by YE2026. The company also recently completed the BLA filing for veli. FDA acceptance in late- Dec/early-Jan will determine whether a Priority Review is granted for a potential mid-2026 approval.
BTIG
$61
Buy
121.82%
Upside
Reiterated
11/04/25
Viridian Therapeutics: Promising Future with Strategic Advancements and Financial BackingWe continue to see the data as considerably de-risked by THRIVE-1/2 given veligrotug and VRDN-003 share the same binding domain. We also expect payers to prefer an SC administered option, and we are not aware of any other publicly announced late-stage development efforts of an SC autoinjector IGF-1R Tx option besides VRDN-003. If this competitive positioning remains unchanged, we expect Viridian to corner most of the TED market later this decade with the best-in-category SC Tx option. If positive, REVEAL-1/2 are expected to support a VRDN-003 BLA submission in YE26.
LifeSci Capital
$46
Buy
67.27%
Upside
Reiterated
11/03/25
Viridian Therapeutics: Promising Prospects with Innovative TED Treatments and Financial Stability Justify Buy RatingDespite the ongoing government shutdown, Viridian (Nasdaq: VRDN) announced that it successfully submied a BLA in late October for veligrotug (an-IGF-1R mAb) in following “producve engagements with the FDA.” The filing was based on posive results from the THRIVE program in both acve and chronic TED paents (our notes HERE and HERE) and includes a request for Priority Review (supported by veligrotug’s Breakthrough Therapy Designaon), which could enable a mid-2026 commercial launch if approved. The FDA will decide whether to accept/file the BLA for review within 60 days of submission.
TD Cowen
―
Buy
―
Reiterated
11/03/25
Leerink Partners
―
Buy
―
Reiterated
10/21/25
Bloom Burton
$13.95
Buy
-49.28%
Downside
Reiterated
10/21/25
Stifel Nicolaus
$41
Buy
49.09%
Upside
Assigned
10/20/25
Jefferies
$44
Buy
60.00%
Upside
Reiterated
10/17/25
Evercore ISI
$38
Buy
38.18%
Upside
Reiterated
08/11/25
Wells Fargo
$26
Hold
-5.45%
Downside
Reiterated
08/06/25
Best Analysts Covering Viridian Therapeutics
1 Month
xxx
Success Rate
14/29 ratings generated profit
Average Return
+3.32%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 48.28% of your transactions generating a profit, with an average return of +3.32% per trade.
3 Months
xxx
Success Rate
15/29 ratings generated profit
Average Return
+6.78%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 51.72% of your transactions generating a profit, with an average return of +6.78% per trade.
1 Year
Success Rate
25/43 ratings generated profit
Average Return
+5.84%
reiterated a buy rating 3 days ago
Copying Laura Chico's trades and holding each position for 1 Year would result in 58.14% of your transactions generating a profit, with an average return of +5.84% per trade.
2 Years
xxx
Success Rate
16/20 ratings generated profit
Average Return
+21.49%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +21.49% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
VRDN Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
17
12
16
19
14
Buy
5
3
4
7
11
Hold
12
10
8
3
2
Sell
1
0
0
0
0
Strong Sell
0
0
0
0
0
total
35
25
28
29
27
Each month's total comprises the sum of three months' worth of ratings.
VRDN Financial Forecast
VRDN Stock Forecast FAQ
What is VRDN’s average 12-month price target, according to analysts?
Based on analyst ratings, Viridian Therapeutics’s 12-month average price target is 39.58.
What is VRDN’s upside potential, based on the analysts’ average price target?
Viridian Therapeutics has 43.93% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is VRDN a Buy, Sell or Hold?
Viridian Therapeutics has a consensus rating of Strong Buy which is based on 14 buy ratings, 0 hold ratings and 0 sell ratings.
What is Viridian Therapeutics’s price target?
The average price target for Viridian Therapeutics is 39.58. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $61.00 ,the lowest forecast is $13.95. The average price target represents 43.93% Increase from the current price of $27.5.
The highest analyst price target is $61.00 ,the lowest forecast is $13.95. The average price target represents 43.93% Increase from the current price of $27.5.
What do analysts say about Viridian Therapeutics?
Viridian Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
How can I buy shares of VRDN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.